Cargando…

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer

Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulivi, Paola, Canale, Matteo, Passardi, Alessandro, Marisi, Giorgia, Valgiusti, Martina, Frassineti, Giovanni Luca, Calistri, Daniele, Amadori, Dino, Scarpi, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796251/
https://www.ncbi.nlm.nih.gov/pubmed/29361687
http://dx.doi.org/10.3390/ijms19010307
_version_ 1783297468674342912
author Ulivi, Paola
Canale, Matteo
Passardi, Alessandro
Marisi, Giorgia
Valgiusti, Martina
Frassineti, Giovanni Luca
Calistri, Daniele
Amadori, Dino
Scarpi, Emanuela
author_facet Ulivi, Paola
Canale, Matteo
Passardi, Alessandro
Marisi, Giorgia
Valgiusti, Martina
Frassineti, Giovanni Luca
Calistri, Daniele
Amadori, Dino
Scarpi, Emanuela
author_sort Ulivi, Paola
collection PubMed
description Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa). We then analyzed a panel of circulating miRNAs in relation to the patient outcome. In multivariate analysis, circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p resulted in being significantly associated with progression-free survival (PFS) (p = 0.027, p = 0.034 and p = 0.039, respectively) and overall survival (OS) (p = 0.044, p = 0.024 and p = 0.032, respectively). We also observed that an increase in hsa-miR-155-5p at the first clinical evaluation was significantly associated with shorter PFS (HR 3.03 (95% CI 1.06–9.09), p = 0.040) and OS (HR 3.45 (95% CI 1.18–10.00), p = 0.024), with PFS and OS of 9.5 (95% CI 6.8–18.7) and 15.9 (95% CI 8.4–not reached), respectively, in patients with an increase ≥30% of hsa-miR-155-5p and 22.3 (95% CI 10.2–25.5) and 42.9 (24.8–not reached) months, respectively, in patients without such increase. In conclusion, our results highlight the potential usefulness of circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p in predicting the outcome of patients with mCRC treated with B. In addition, the variation of circulating hsa-miR-155-5p could also be indicative of the patient survival.
format Online
Article
Text
id pubmed-5796251
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57962512018-02-09 Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer Ulivi, Paola Canale, Matteo Passardi, Alessandro Marisi, Giorgia Valgiusti, Martina Frassineti, Giovanni Luca Calistri, Daniele Amadori, Dino Scarpi, Emanuela Int J Mol Sci Article Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa). We then analyzed a panel of circulating miRNAs in relation to the patient outcome. In multivariate analysis, circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p resulted in being significantly associated with progression-free survival (PFS) (p = 0.027, p = 0.034 and p = 0.039, respectively) and overall survival (OS) (p = 0.044, p = 0.024 and p = 0.032, respectively). We also observed that an increase in hsa-miR-155-5p at the first clinical evaluation was significantly associated with shorter PFS (HR 3.03 (95% CI 1.06–9.09), p = 0.040) and OS (HR 3.45 (95% CI 1.18–10.00), p = 0.024), with PFS and OS of 9.5 (95% CI 6.8–18.7) and 15.9 (95% CI 8.4–not reached), respectively, in patients with an increase ≥30% of hsa-miR-155-5p and 22.3 (95% CI 10.2–25.5) and 42.9 (24.8–not reached) months, respectively, in patients without such increase. In conclusion, our results highlight the potential usefulness of circulating basal levels of hsa-miR-20b-5p, hsa-miR-29b-3p and hsa-miR-155-5p in predicting the outcome of patients with mCRC treated with B. In addition, the variation of circulating hsa-miR-155-5p could also be indicative of the patient survival. MDPI 2018-01-20 /pmc/articles/PMC5796251/ /pubmed/29361687 http://dx.doi.org/10.3390/ijms19010307 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ulivi, Paola
Canale, Matteo
Passardi, Alessandro
Marisi, Giorgia
Valgiusti, Martina
Frassineti, Giovanni Luca
Calistri, Daniele
Amadori, Dino
Scarpi, Emanuela
Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
title Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
title_full Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
title_fullStr Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
title_full_unstemmed Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
title_short Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
title_sort circulating plasma levels of mir-20b, mir-29b and mir-155 as predictors of bevacizumab efficacy in patients with metastatic colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796251/
https://www.ncbi.nlm.nih.gov/pubmed/29361687
http://dx.doi.org/10.3390/ijms19010307
work_keys_str_mv AT ulivipaola circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT canalematteo circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT passardialessandro circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT marisigiorgia circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT valgiustimartina circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT frassinetigiovanniluca circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT calistridaniele circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT amadoridino circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer
AT scarpiemanuela circulatingplasmalevelsofmir20bmir29bandmir155aspredictorsofbevacizumabefficacyinpatientswithmetastaticcolorectalcancer